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ABSTRACT 
Introduction: Urinary bladder cancer (UBC) is the second most frequent 
malignancy of the urinary system and the ninth most common cancer 
worldwide, affecting individuals over the age of 65. Several investigations have 
embarked on advancing knowledge of the mechanisms underlying urothelial 
carcinogenesis, understanding the mechanisms of antineoplastic drugs 
resistance and discovering new antineoplastic drugs. In vitro and in vivo models 
are crucial for providing additional insights into the mechanisms of urothelial 
carcinogenesis. With these models, various molecular pathways involved in 
urothelial carcinogenesis have been discovered, allowing therapeutic 
manipulation. 
Areas covered: This paper provides critical information on existing in 
vitro and in vivomodels to screen the efficacy and toxicity of innovative UBC 
therapies and point out the challenges for new and improved models. 
Expert opinion: In our opinion, results obtained with in vitro and in vivo models 
should be interpreted together, as a set of delicate biological tools that can be 
used at different stages in the drug discovery process, to address specific 
questions. With the development of new technologies, new assays and 
biomarkers are going to play an important role in the study of UBC. The 
molecular diagnostics and genomic revolution will not only help to develop new 
drug therapies, but also to achieve tailored therapies. 
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